A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Luke Mantle
Study ID
Protocol Number: 23-2225
More information available at ClinicalTrials.gov: NCT06112314
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers